T1	AdverseReaction 30 74	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
T2	AdverseReaction 82 94	MALIGNANCIES
T3	AdverseReaction 108 118	INFECTIONS
T4	Severity 100 107	SERIOUS
T5	AdverseReaction 131 175	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
T6	AdverseReaction 183 195	MALIGNANCIES
T7	AdverseReaction 209 219	INFECTIONS
T8	Severity 201 208	SERIOUS
T9	AdverseReaction 255 299	post-transplant lymphoproliferative disorder
T10	AdverseReaction 301 305	PTLD
T11	Factor 235 239	risk
T12	AdverseReaction 1146 1183	Increased susceptibility to infection
T13	AdverseReaction 1216 1228	malignancies
T15	Factor 1229 1232	may
T14	AdverseReaction 1519 1563	POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
T16	AdverseReaction 1571 1583	MALIGNANCIES
T17	AdverseReaction 1597 1607	INFECTIONS
T18	Severity 1589 1596	SERIOUS
T19	AdverseReaction 1718 1762	post-transplant lymphoproliferative disorder
T20	AdverseReaction 1764 1768	PTLD
T21	Factor 1698 1702	risk
T22	AdverseReaction 2223 2260	Increased susceptibility to infection
T23	AdverseReaction 2293 2305	malignancies
T24	Factor 2306 2309	may
E1	AdverseReaction:T1
E2	AdverseReaction:T2
E3	AdverseReaction:T3 Effect:E4
E4	Severity:T4
E5	AdverseReaction:T5
E6	AdverseReaction:T6
E7	AdverseReaction:T7 Effect:E8
E8	Severity:T8
E9	AdverseReaction:T9 Hypothetical:E11
E10	AdverseReaction:T10
E11	Factor:T11
E12	AdverseReaction:T12 Hypothetical:E15
E13	AdverseReaction:T13 Hypothetical2:E15
E15	Factor:T15
E14	AdverseReaction:T14
E16	AdverseReaction:T16
E17	AdverseReaction:T17 Effect:E18
E18	Severity:T18
E19	AdverseReaction:T19 Hypothetical:E21
E20	AdverseReaction:T20
E21	Factor:T21
E22	AdverseReaction:T22 Hypothetical:E24
E23	AdverseReaction:T23 Hypothetical:E24
E24	Factor:T24
A1	CUI E1 C0432487
A2	UMLS-Preferred-Name E1 Post-transplant lymphoproliferative disorder
A3	MEDDRA-PT E1 Post transplant lymphoproliferative disorder
A4	MEDDRA-PT-ID E1 10051358
A5	CUI E2 C0006826
A6	UMLS-Preferred-Name E2 Malignant Neoplasms
A7	MEDDRA-PT E2 Neoplasm malignant
A8	MEDDRA-PT-ID E2 10028997
A9	CUI E3 C3714514
A10	UMLS-Preferred-Name E3 Infection
A11	MEDDRA-PT E3 Infection
A12	MEDDRA-PT-ID E3 10021789
A13	CUI E5 C0432487
A14	UMLS-Preferred-Name E5 Post-transplant lymphoproliferative disorder
A15	MEDDRA-PT E5 Post transplant lymphoproliferative disorder
A16	MEDDRA-PT-ID E5 10051358
A17	CUI E6 C0006826
A18	UMLS-Preferred-Name E6 Malignant Neoplasms
A19	MEDDRA-PT E6 Neoplasm malignant
A20	MEDDRA-PT-ID E6 10028997
A21	CUI E7 C3714514
A22	UMLS-Preferred-Name E7 Infection
A23	MEDDRA-PT E7 Infection
A24	MEDDRA-PT-ID E7 10021789
A25	CUI E9 C0432487
A26	UMLS-Preferred-Name E9 Post-transplant lymphoproliferative disorder
A27	MEDDRA-PT E9 Post transplant lymphoproliferative disorder
A28	MEDDRA-PT-ID E9 10051358
A29	CUI E10 C0432487
A30	UMLS-Preferred-Name E10 Post-transplant lymphoproliferative disorder
A31	MEDDRA-PT E10 Post transplant lymphoproliferative disorder
A32	MEDDRA-PT-ID E10 10051358
A33	CUI E12 C0236171
A34	UMLS-Preferred-Name E12 Increased susceptibility to infections
A35	MEDDRA-PT E12 Infection susceptibility increased
A36	MEDDRA-PT-ID E12 10021866
A37	CUI E13 C0006826
A38	UMLS-Preferred-Name E13 Malignant Neoplasms
A39	MEDDRA-PT E13 Neoplasm malignant
A40	MEDDRA-PT-ID E13 10028997
A41	CUI E14 C0432487
A42	UMLS-Preferred-Name E14 Post-transplant lymphoproliferative disorder
A43	MEDDRA-PT E14 Post transplant lymphoproliferative disorder
A44	MEDDRA-PT-ID E14 10051358
A45	CUI E16 C0006826
A46	UMLS-Preferred-Name E16 Malignant Neoplasms
A47	MEDDRA-PT E16 Neoplasm malignant
A48	MEDDRA-PT-ID E16 10028997
A49	CUI E17 C3714514
A50	UMLS-Preferred-Name E17 Infection
A51	MEDDRA-PT E17 Infection
A52	MEDDRA-PT-ID E17 10021789
A53	CUI E19 C0432487
A54	UMLS-Preferred-Name E19 Post-transplant lymphoproliferative disorder
A55	MEDDRA-PT E19 Post transplant lymphoproliferative disorder
A56	MEDDRA-PT-ID E19 10051358
A57	CUI E20 C0432487
A58	UMLS-Preferred-Name E20 Post-transplant lymphoproliferative disorder
A59	MEDDRA-PT E20 Post transplant lymphoproliferative disorder
A60	MEDDRA-PT-ID E20 10051358
A61	CUI E22 C0236171
A62	UMLS-Preferred-Name E22 Increased susceptibility to infections
A63	MEDDRA-PT E22 Infection susceptibility increased
A64	MEDDRA-PT-ID E22 10021866
A65	CUI E23 C0006826
A66	UMLS-Preferred-Name E23 Malignant Neoplasms
A67	MEDDRA-PT E23 Neoplasm malignant
A68	MEDDRA-PT-ID E23 10028997
